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treatment of solid tumors. In the present study, we have exam-
ined the applicability and efficacy of LTX-401 in a rat model
JM1 hepatocellular carcinoma, with particular interest in its
ability to induce antitumor immunity. LTX-401 induces
necrotic cell death followed by the release of immunogenic
cell deathmediators such as high-mobility group box 1 protein,
ATP, and cytochrome c. When injected into subcutaneous
and orthotopic JM1 tumors, LTX-401 treatment resulted in a
strong antitumoral effect followed by complete tumor regres-
sion in the majority of animals. Additionally, LTX-401 could
affect the growth of distal tumor deposits simulating metasta-
ses, hence indicating immune-mediated abscopal responses.
Furthermore, LTX-401 treatment induced tumor-specific
immune responses as seen by protection against tumor rechal-
lenge and increased production of interferon-gamma (IFN-g)
by splenic cells in response to stimulation with tumor cells.
Taken together, our data demonstrate that the oncolytic com-
pound LTX-401 provides local tumor control followed by
protective immune responses and may be exploited as a novel
immunotherapeutic agent in hepatocellular carcinoma.Received 15 January 2019; accepted 9 May 2019;
https://doi.org/10.1016/j.omto.2019.05.002.
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Liver cancer is estimated to be the third most common cause of can-
cer-related mortality globally, with incidence rates more than tripled
since 1980.1,2 Hepatocellular carcinoma (HCC) is the most frequent
type of primary liver cancer, accounting for 90% of hepatic malig-
nancies.3 If diagnosed at an early stage, HCC is potentially curable by
surgical procedures such as resection, transplantation, and minimally
invasive ablation techniques. However, less than 20% of patients are
eligible for such treatments.4,5 The vast majority of patients with
HCC are diagnosed in late stages of the disease, hence leading to
poor prognosis because of limited treatment options. Sorafenib, a
multi-kinase inhibitor, has long been the only approved systemic
treatment for advanced-stage HCC. More recently, however, the
multi-kinase inhibitor lenvatinib also gained approval as a first-line
treatment of patients with unresectable HCC. Despite being shown
to confer some mortality benefit, lenvatinib extended median survivalMolecular Ther
This is an open access article under the CC BY-NC-time by only 1.3 months compared with sorafenib,6 hence illustrating
the impending need to pursue new and improved therapeutic ap-
proaches. Currently, different classes of immunotherapeutic agents
are being investigated in patients with advanced-stage HCC.7,8
Among these, monoclonal antibodies specifically targeting the immu-
noinhibitory PD-1 and PD-L1 axis have shown great potential in
clinical trials, with reports of clinically meaningful and durable
responses.9,10
Anticancer peptides (ACPs), otherwise known as oncolytic peptides,
represent a novel class of immunotherapeutics displaying broad-spec-
trum cytotoxic activity that is unaffected by multidrug resistance
mechanisms.11–13 Cell death often occurs through primary necrosis,
owing predominantly to the membranolytic mode of action. As a
result, ACP-induced cancer cell death may potentially liberate tumor
antigens and immunomodulatory components to prime tumor-
specific T cells and promote antitumor immunity. This scenario is
seemingly linked to the induction of immunogenic cell death
(ICD), which is characterized by the cell-surface exposure and/or
release of damage-associated molecular pattern molecules (DAMPs)
such as calreticulin, ATP, and high-mobility group box 1 protein
(HMGB1), which attract dendritic cell precursors to the proximity
of dying cancer cells and stimulate the uptake of dead cell-associated
antigens followed by optimal tumor antigen cross-presentation to
ignite cytotoxic T lymphocyte responses.14–17
Because oncolytic peptides are now being optimized for the treatment
of cancer, we attempted to develop smaller derivates with bulky and
lipophilic moieties for improved stability and anticancer activity. The
resulting amphipathic b(2,2)-amino acid derivative LTX-401 (Fig-
ure 1), formerly known as BAA-1,18 resembles larger oncolytic pep-
tides with respect to hydrophobicity and cationicity, thereby enablingapy: Oncolytics Vol. 14 September 2019 ª 2019 The Author(s). 139
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Chemical Structure of LTX-401 [N-(2-Aminoethyl)-2-
(Aminomethyl)-5-Phenyl-2-(3-Phenylpropyl)Pentanamide]
Molecular Therapy: Oncolyticsit to interact with and permeabilize cancer cell membranes. LTX-401
also exerts cytotoxic activity against normal cell lines, but displays
selectivity to human red blood cells.19 Considering its intended use
as a locally administered agent, the selectivity toward normal cells
is of less importance compared with systemic interventions. Local
administration of LTX-401 into subcutaneously (s.c.) established
B16 melanomas and MCA205 sarcomas has been found to induce
focal tumor necrosis, followed by lymphoid infiltration and subse-
quent complete regression.19,20 In the present study, we expand
upon our previous findings and investigate the applicability and
efficacy of LTX-401 against both s.c. and orthotopic tumors in an
immunocompetent rat model of HCC.RESULTS
LTX-401 Rapidly Kills JM1 Cells
The MTT cell viability assay21 was employed in order to evaluate the
cytotoxic activity and time course of killing (kinetics) by LTX-401
against JM1 cells. Both concentrations tested led to similar killing
kinetics after 30 min of incubation, with cellular survival rate just
beneath 50% (Figure 2). Within 90 min, LTX-401 had effectively
killed nearly 100% of the cells, leaving a small subset of JM1 cells still
metabolically active. In contrast, the chemotherapeutic agents doxo-
rubicin and gemcitabine required a significantly longer incubation
period to exert a similar cytotoxic effect against JM1 cells (Figure S1).
Together, these data demonstrate that LTX-401 is a fast-acting and
potent anticancer compound.LTX-401 Induces Morphological Signs of Necrotic Cell Death
and Promotes Release of DAMPs from JM1 Cells
Due to the rapid mechanism of action, we hypothesized that LTX-401
induced primary necrosis. Following 60 min of incubation, electron
microscopic examination of LTX-401-treated JM1 cells revealed
increased cellular volume caused by swelling (oncosis), formation
of intracellular vacuoles, and diminished plasma membrane integrity
without drastic morphological changes in nuclei (Figures 3E and 3F)
compared with control cells (Figures 3A and 3B). Moreover, distorted
cell morphology was even observed after 5 min of incubation with
LTX-401 that manifested itself in loss or reduction of cell surface
(microvillus-like pseudopods) and moderate oncosis (Figures 3C
and 3D). Higher magnification (30,000) also revealed clear alter-
ations in normal morphology of intracellular organelles, particularly140 Molecular Therapy: Oncolytics Vol. 14 September 2019in mitochondria, whose inner micro-compartments (cristae) were
severely swollen and disintegrated (Figure 3H) compared with con-
trol cells (Figure 3G). Altogether, these data point toward the
ability of LTX-401 to induce necrotic cancer cell death.
Next, we wanted to investigate the capacity of LTX-401 to stimulate
features of ICD by analyzing the release of selected DAMPs into
the culture supernatants of LTX-401-treated JM1 cells. HMGB1, a
highly conserved non-histone chromatin binding protein, occupies
a critical role as a proinflammatory mediator because of its ability
to engage multiple surface receptors on immune cells once released
into the extracellular milieu.22 Here, HMGB1 was detected in cell
culture supernatants (after 60 min) by western blot analysis when
treated with 108 mM LTX-401 (Figure 4A). Control cells preserved
in serum-free RPMI 1640 showed complete detainment of the protein
only within the lysates.
As withHMGB1, the release of ATP from dying cells constitutes one of
the major hallmarks of ICD.23 When incubated with 54 mM LTX-401,
the extracellular concentration of ATP quickly increased after 60 min
of treatment (Figure 4B), as measured by means of a bioluminescence
reaction (luciferase assay). Moreover, a peak was observed at 90 min
into LTX-401 treatment before declining toward 2 h of incubation.
A cytochrome c ELISA assay was carried out to further assess the
capability of LTX-401 to release mitochondrial DAMPs. Transloca-
tion of cytochrome c into the extracellular space has been reported
to trigger inflammation by modulating the production of pro-inflam-
matory cytokines and chemokines via activation of the NF-kB
pathway.24 A significant amount of cytochrome c was found in cell
culture supernatants after 1 h of incubation with 108 mM LTX-401
(Figure 4C). Cytochrome c was not detectable in the supernatant
fraction of untreated control cells. Altogether, these studies indicate
that LTX-401 is able to stimulate features of ICD.
Treatment with LTX-401 Leads to the Release of ROS
Based on the observed effect on intracellular organelles, we hypoth-
esized that LTX-401 would promote the production of reactive
oxygen species (ROS). When incubating JM1 cells with 271 mM
LTX-401, we observed a 2-fold increase in ROS production as
measured by fluorescence intensity relative to control values (Fig-
ure 4D). Although lower doses of LTX-401 could induce the release
of ROS from JM1 cells, a higher dose was chosen to indicate a
significant effect. It is likely that the release of ROS is secondary
to plasma membrane rupture, as ROS is primarily located in mito-
chondria. The reason for the differences in LTX-401 concentration
across various in vitro studies was based on initial pilot studies
demonstrating that different concentrations were needed to induce
the release of DAMPs.
LTX-401 Induces Complete Regression of Subcutaneous JM1
Tumors
In order to investigate the direct antitumor effects of LTX-401, syn-
geneic Fisher 344 rats with day 7 or 8 s.c. JM1 tumors (60–90 mm3)
Figure 2. Killing Kinetics of JM1 Cells Treated with LTX-401
Cells were treated with 54 and 108 mM LTX-401 for designated time points (5, 15,
30, 60, 90, 120, and 240 min) and assessed for viability using the MTT assay. Data
represent the mean ± SD of three independent experiments with triplicates for each.
www.moleculartherapy.orgwere treated with either single doses of LTX-401 (n = 10) or vehicle
control (n = 5) for 3 consecutive days (Figure 5A). Seven out of 10
tumor-bearing rats were cured by LTX-401 treatment (Figures 5B
and 5C), whereas all animals in the control group had to be eutha-
nized by day 23 post-inoculation because of tumor overburden
and/or severe ulceration. Animals cured by LTX-401 treatment
(n = 7) were rechallenged with 1 105 viable JM1 cells in the contra-
lateral flank of the abdomen 4 weeks after complete regression. All
animals resisted tumor development despite initially having slight
tumor growth. In contrast, naive recipients (n = 4) all rapidly devel-
oped tumor (Figures 5D and 5E). In order to examine systemic
protective immune responses, animals surviving second tumor
challenge (s.c.) were additionally implanted orthotopically with
live JM1 cells in the inferior right liver lobe. All animals previously
cured by LTX-401 (n = 7) were resistant against intrahepatic tumor
growth, whereas control animals (n = 4) all developed tumors and
had to be sacrificed within 26 days post-inoculation because
of excess tumor burden and general health condition (Figures 5F
and 5G).
LTX-401 Treatment Mediates Abscopal Effects
To examine the ability of LTX-401 to affect a distal tumor deposit,
we applied a two-tumor model in which the size of an intrahepatic
tumor was measured after treating a s.c. established tumor (Fig-
ure 6A). Three consecutive injections of LTX-401 led to a complete
response at the initial tumor site (Figure 6B) and was sufficient in
controlling the growth of an untreated intrahepatic tumor
compared with control animals treated with sterile saline (Figures
6C and 6D). However, the abscopal effect was statistically more sig-
nificant at day 18 (9 days after the last LTX-401 injection) compared
to day 21 (s.c. tumor endpoint). Taken together, these data indicate
that LTX-401 is capable of inducing a partial immune-mediated
abscopal effect.LTX-401 Treatment Induces Complete Regression of Orthotopic
JM1 Liver Tumors andGenerates Long-TermProtective Immune
Responses
Next, we wanted to investigate the direct antitumor effects of LTX-
401 against orthotopic JM1 liver tumors, hence mimicking clinical
HCC. Rats bearing JM1 tumors (30–60 mm3) in the inferior left liver
lobe were given two injections of 1.5 mg LTX-401 (n = 9) on days 6
and 8, whereas control animals (n = 5) received vehicle solution (Fig-
ure 7A). Five out of nine intrahepatic tumor-bearing rats were cured
by LTX-401 treatment (Figures 7B and 7C). Control animals were
sacrificed by day 24 post-inoculation because of tumor overburden
and general health condition. We did not experience any drug-related
or treatment-related adverse events by intratumoral injection of LTX-
401 in these studies. Ultrasound monitoring post-treatment revealed
extensive tumor necrosis that slowly regressed the following months
(Figure 7G). Tumor-free animals (n = 5) were rechallenged with
1 105 viable JM1 cells s.c. 4 weeks after complete regression of intra-
hepatic tumors. All animals resisted rechallenge, indicating systemic
protection, except one animal that started to develop s.c. tumor
70 days after tumor inoculation (Figures 7D and 7E). We next
measured interferon-gamma (IFN-g) production in response to
(tumor) restimulation as a marker for T cell activity. Splenocytes har-
vested from animals that resisted s.c. rechallenge (n = 4) demon-
strated increased IFN-g production in response to irradiated JM1
cells compared with splenocytes taken from naive control animals
(Figure 7F).
Histopathological Examination
In the untreated rats, well-circumscribed tumors were seen in the
s.c. fat tissue or in the liver tissue (Figures 8A and 8C). The immune
infiltrate consisted of NK cells and CD3+ T cells whereof the majority
were CD8+ T cells as shown by immunohistochemistry (IHC) (Fig-
ures 8E–8P). Tumors injected with LTX-401 were largely necrotic
(Figures 8B and 8D), and some necrosis was also observed in adjacent
liver tissue, likely caused by leakage from the tumor. Surrounding the
areas with induced necrosis, a rim of granulation tissue was seen. The
inflammatory infiltrate at the border of the tumors and necrotic tissue
was similar to the untreated rats. Masson-trichrome staining showed
no fibrosis in control tumors and only low levels of collagen at the
border of the necrotic tissue in LTX-401-treated animals (Figures
8Q and 8R). Animals bearing intrahepatic tumor that were cured
by LTX-401 treatment displayed no remaining tumor tissue,
and Masson-trichrome staining revealed livers with small areas
of collagen-rich fibrosis with thin and thick-walled vessels and
collections of pigment macrophages, but without prominent
inflammation.
DISCUSSION
The complete failure of tumor-debulking therapies, such as systemic
chemotherapy, has gradually shifted the treatment of advanced HCC
toward molecular-targeted therapies. However, survival benefits vary
significantly among patients likely because of the complexity of hep-
atocarcinogenesis and heterogeneity of HCC.25 There is increasing
evidence to support that solid tumors are composed of heterogenousMolecular Therapy: Oncolytics Vol. 14 September 2019 141
Figure 3. Treatment with LTX-401 Leads to Ultrastructural Changes in JM1 Cells
Cells were treated with 108 mM LTX-401 for various time points (5 and 60 min) before being fixed in a PHEM-buffered malachite green fixative and prepared for electron
microscopy studies. Untreated control cells (A, B, and G) were preserved in serum-free RPMI 1640 (vehicle control) until experimental endpoint (60 min) and compared with
cells treated for 5 (C and D) and 60 min (E, F, and H).
Molecular Therapy: Oncolyticstumor cell populations expressing different tumor antigens. As such,
tumor heterogeneity contributes to drug resistance and disease recur-
rence following therapy and imposes a substantial obstruction to the
development of effective cancer treatments.26–28 Targeted therapies
may also aid in the selection of more invasive and resistant clones
by eliminating the therapy-sensitive sub-clones.29 A novel approach
for tackling tumor heterogeneity can involve immunotherapy.
Augmentation of immune responses against tumor antigens is
likely one of the most effective ways to therapeutically influence the
host-cancer interaction. Hence therapies designed to maximize the
liberation of tumor antigens in an immunogenic fashion could prove
beneficial for mounting immune responses directed against several
antigens, thus addressing heterogeneity. Here, we demonstrate that
the novel anticancer compound LTX-401 exerts a membrane pertur-
bating (oncolytic) effect on JM1 hepatoma cells with subsequent
release of immunogenic mediators such as HMGB1, ATP, and cyto-
chrome c. These observations suggest that LTX-401 is capable of
releasing the full spectrum of tumor antigens, which explains why142 Molecular Therapy: Oncolytics Vol. 14 September 2019intratumoral treatment of both s.c. and orthotopic tumors led to
complete regression and long-term protective immune responses.
Other anti-cancer agents known to induce ICD and tumor antigen
release include doxorubicin, which is often applied in chemoemboli-
zation procedures against intermediate-stage HCC. However, recur-
rence rates are high and once progressing into advanced HCC,
chemotherapeutic regimens are typically not well tolerated because
of underlying hepatic dysfunction.
Our study also demonstrates the ability of LTX-401 to mediate (par-
tial) abscopal effects, which, undoubtedly, is one of the major goals
of local immunotherapy. However, we did not observe a complete
regression in the distant intrahepatic tumor, which is likely due to
established local immunosuppression that counteracts antitumor
immunity.30 Nevertheless, an abscopal effect implies that LTX-401
induced tumor antigen release and ICD within the treated lesion to
prime (systemic) antitumor T cell responses. The latter is also sup-
ported by experiments where animals cured by LTX-401 treatment,
Figure 4. JM1 Cells Release DAMPs and ROS When
Treated with LTX-401
(A) JM1 cells release HMGB1 from the lysate (L) to super-
natant (S) after being stimulated with 108 mM LTX-401. (B)
ATP is released from JM1 cells into supernatant following
treatment with 54 mM LTX-401. (C) Release of cytochrome c
into supernatant of LTX-401-treated JM1 cells (108 mM). (D)
JM1 cells release ROS after being treated with 271 mM LTX-
401 for 45 min. Data are expressed as fold-change in ROS
release relative to control. For (B)–(D), data depict the
mean ± SEM. *p < 0.05, **p < 0.01, ****p < 0.0001 by
Kruskal-Wallis test (B and C) and Student’s t test (D).
www.moleculartherapy.orgeither at s.c. or intrahepatic site, were resistant to tumor rechallenge,
thus indicating that a systemic tumor-specific immunological memory
was generated. As shown by ELISpot assay, the presence of markedly
higher IFN-g production by splenocytes harvested from cured animals
accentuates the capacity of LTX-401 to induce antitumor immune re-
sponses. An increased expression of Th1 cytokines, such as IFN-g, is
known to positively correlate with prognosis and survival in several
malignancies,31,32 and is applied as a marker to reveal tumor-specific
lymphocytes in response to tumor antigen stimulation. Despite
observing a slight increase of T cell and NK cell infiltration in s.c.
tumors after treatment, we did not detect a significant change of im-
mune infiltrate in intrahepatic tumors. This might be attributed to
the fact that the carcinogen-induced JM1 tumor model33 is relatively
immunogenic, thus attracting immune cells to the tumor parenchyma.
Moreover, as seen in intrahepatic control tumors, large areas of the
center core were necrotic. Rapidly growing tumors are frequently
deprived of oxygen (hypoxia), which may result in necrotic cell death
and tumor-elicited inflammation.34 However, evidence suggests that
hypoxia-induced leukocyte recruitment promotes cancer progression
and increases metastatic potential, as well as immunosuppression.35,36
In view of these considerations, we speculate that LTX-401 is capable
of reshaping the tumor microenvironment, hence tipping the balance
toward effective antitumor immune responses. The observation that
LTX-401 induces T cell infiltration and complete regression of poorly
immunogenic B16 melanomas19 provides additional support for this
hypothesis. However, further immune cell phenotyping studies are
required to characterize the changes in the tumor microenvironment
following LTX-401 treatment.
Direct percutaneous-based treatment options like radiofrequency or
ethanol ablation are already standard of care in selected primaryMolecular Ttumors or metastases in the liver with a diameter
less than 30mm. These modalities use direct intra-
tumoral puncture or injection under imaging guid-
ance. Although LTX-401 was administered into
orthotopic liver tumors without the guidance of
radiological techniques, we did not experience
any surgery- or treatment-related difficulties or
adverse events. Onemight speculate a variable pre-
cision level caused by lack of ultrasonic guidance
could lead to suboptimal local dosage and explainthe therapeutic failure in some animals. In a clinical setting, however,
LTX-401 would have been amenable to injection under radiographic
guidance to specifically elicit maximal effect and necrosis of the tumor
while minimizing necrosis of surrounding healthy liver tissue, which is
the only potential clinical toxicity expected of this therapy considering
the intratumoral route of administration. A histopathological assess-
ment of intrahepatic tumors revealed both unresorbed necrosis and
granulation (healing) tissue post-treatment, which was in accordance
with ultrasound scans showing the presence of a well-defined round
shape without typical tumor morphology 2 weeks after treatment.
Ultrasound scans and tissue samples taken 3months after tumor treat-
ment displayed healthy and tumor-free livers, indicating regeneration
of liver parenchymal tissue in the area of tumor necrosis. Finally, toxi-
cology studies conducted in rats have demonstrated that LTX-401 is
generally well tolerated at both intravenous and direct intrahepatic
administration, and that high doses (>10 mg/kg) are required to
identify dose-limiting toxicity.
Conclusions
Taken together, the present study demonstrates that LTX-401 has the
potential to stimulate anticancer immune responses and may be
applied therapeutically as a novel antitumor and immunotherapeutic
approach in HCC. Further studies are required to assess the potential




LTX-401 (molecular weight [MW]net = 367.53) was synthetized and
provided by Synthetica AS (Oslo, Norway). LTX-401 was dissolved
in serum-free RPMI 1640 unless stated otherwise.herapy: Oncolytics Vol. 14 September 2019 143
Figure 5. Therapeutic Efficacy of LTX-401 against Subcutaneous JM1 Tumors
(A) Schematic depiction of the treatment schedule in a syngeneic tumor model in immunocompetent Fisher 344 rats inoculated subcutaneously with 1 105 JM1 hepatoma
cells. Subcutaneous JM1 tumors were injected intratumorally with either (B) sterile 0.9%NaCl (control) or 0.4 mg LTX-401 once a day for 3 consecutive days (7, 8, and 9) after
tumor cell inoculation. (C) Survival cures of animals treated with LTX-401. (D) Animals surviving primary tumor challenge were rechallenged subcutaneously with 1 105 viable
JM1 cells contralateral to the first tumor site andmeasured for tumor growth. (E) Survival curves of subcutaneous rechallenge. (F) Four weeks after subcutaneous rechallenge,
surviving animals were given intrahepatic rechallenge by the direct injection of 1  105 viable JM1 into the inferior right lobe of the liver and measured for tumor growth.
(G) Survival curves of intrahepatic rechallenge. The percentages of surviving animals were analyzed using a log rank Mantel-Cox test. ****p < 0.0001. s.c., subcutaneous.
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JM1 HCC cells33,37 were cultured in DMEM (Sigma) supplemented
with 10% heat-inactivated fetal bovine serum (FBS) (GIBCO) and
kept under standard cell culture conditions (37C, <95% humidity,
and 5% CO2).
Kinetic Analysis
Cells were incubated with LTX-401 solutions (both 2  IC504h =
54 mM and 4  IC504h value = 108 mM; where IC504h is the half
maximum inhibitory concentration after 4 h) for 5, 15, 30, 60,
90, 120, and 240 min before being washed once with serum-free
RPMI 1640 and further incubated in a 10% MTT solution (diluted
in serum-free RPMI 1640) for an additional 2 h. Lastly, acidified
isopropanol was added to facilitate formazan crystal solubilization.144 Molecular Therapy: Oncolytics Vol. 14 September 2019Absorbance was measured at 570 nm on a spectrophotometric mi-
crotiter plate reader (Thermomax Molecular Devices, NJ, USA).
Cell survival was calculated as the A570 nm of treated cells relative
to the negative control (100% viable cells) using the mean of two
or three independent experiments and expressed as a 50% inhibi-
tory concentration (IC50). For experiments comparing the cyto-
toxic activity of LTX-401 against doxorubicin and gemcitabine,
the 2  IC5048h was chosen to display differences in killing
kinetics because the chemotherapeutic agents required longer in-
cubation periods to reach IC50 values. IC50 values were determined
by dilution series; 2.7–272 mM for LTX-401 and 0.01–100 mM for
doxorubicin and gemcitabine. Recordings were made at 4, 24, and
48 h. The reason for the differences in LTX-401 concentration
across various in vitro studies was based on initial pilot studies
Figure 6. Partial Abscopal Response after Local
Therapy with LTX-401
(A) Schematic depiction of the abscopal tumor model. Ani-
mals were inoculated subcutaneously with 1 105 JM1 cells
on day 0 followed by intrahepatic inoculation with 1  105
JM1 cells on day 6. The subcutaneous tumor was treated
with 0.4 mg LTX-401 per injection or sterile 0.9%
NaCl (control). (B) Subcutaneous (treated) tumor size at
day 21 (tumor endpoint). Intrahepatic (untreated) tumor
size at (C) day 18 and (D) day 21. One dot represents one
animal. *p < 0.05, **p < 0.01, ***p < 0.001 by Mann-Whitney
test.
www.moleculartherapy.orgdemonstrating that different concentrations were needed to induce
the release of DAMPs.
Electron Microscopy
Samples were treated according to previously applied protocol19
involving the use of malachite green fixation and microwave-assisted
processing and embedding for transmission electron microscopy. In
short, cells were treated with LTX-401, harvested at various time
points (5, 30, and 60 min), and prepared for electron microscopy.
Control cells were treated with vehicle control (serum-free RPMI
1640) until experimental endpoint (60 min).
Detection of Extracellular HMGB1
JM1 HCC cells were seeded at a density of 2.0  105 cells/well in
DMEM supplemented with 10% FBS and left to adhere overnight
under standard cell culture conditions. Extracellular HMGB1
following incubation with LTX-401 was detected by western blot
analysis as previously described.19 In short, LTX-401 was diluted in
vehicle (serum-free RPMI 1640), whereas control cells were preserved
in vehicle solution only.
Luciferin-Luciferase Detection of Extracellular ATP
JM1 HCC cells were seeded into 96-well plates at a density of
1.0  104 cells/well, left to adhere overnight, and treated with
54 mM LTX-401 for designated time points (10, 30, 60, 90, and
120 min) the following day. LTX-401-induced ATP secretion was
determined as previously described.19 In short, LTX-401 was diluted
in vehicle (serum-free RPMI 1640), whereas control cells were
preserved in vehicle solution only.
Detection of Extracellular Cytochrome c
For the detection of extracellular cytochrome c, JM1 HCC cells were
cultured and treated with LTX-401 as described previously for theMolecular Tluciferin-luciferase assay. In short, LTX-401 was
diluted in vehicle (serum-free RPMI 1640),
whereas control cells were preserved in vehicle
solution only. Supernatants were diluted 1/5
in serum-free RPMI 1640 before the amount
of cytosolic cytochrome c after treatment with
LTX-401 was quantified using an ELISA-basedcytochrome c detection kit (R&D Systems, USA) according to the
manufacturer’s protocol.
ROS Measurement
JM1 cells were seeded out in clear-bottomed black-sided 96-well plates
at a concentration of 2.5  104 cells/well. Cells were treated with
271 mM LTX-401 (100 mg/mL) for 45 min and analyzed for ROS
release using the 20,70-dichlorofluorescin diacetate (DCFDA) Cellular
ROS Detection Assay Kit from Abcam (ab113851). LTX-401 was dis-
solved in serum-free RPMI 1640 without phenol red (as recommended
in the Assay Kit instructions), andDCFDAwas used at a concentration
of 25 mM. Negative control was cells incubated with serum-free RPMI
1640 without phenol red, and the positive control was 150 mM tert-
butyl hydroperoxide (TBHP).
Animals
Six- to ten-week-old male Fisher 344 rats (170–250 g) were ob-
tained from Taconic Biosciences (Denmark) and housed in cages
(containing one to two rats) specifically designed for rats, with a
12 h/12 h day-night cycle, and allowed ad libitum access to
high-quality rodent chow and water. All animals were monitored
daily by both the animal care staff and researchers for adequacy
of food, water, and general overall health conditions. Rats were
placed individually in an induction chamber, and anesthesia was
induced with 5% isoflurane (Isobar Vet; 100%; Nomeco, Copenha-
gen, Denmark) at 2 L/min mixed with purified oxygen until loss of
righting reflex. Thereafter, rats were placed on their back in a nose
cone, and anesthesia was maintained with a 0.5 L/min 2%–3% iso-
flurane-oxygen mix during tumor cell inoculation, tumor treat-
ment, and surgery. Experiments were in compliance with local
and European Ethical Committee guidelines and were approved
by the Norwegian National Animal Research Authority (NARA
approval ID: 6995).herapy: Oncolytics Vol. 14 September 2019 145
Figure 7. Therapeutic Efficacy of LTX-401 against Orthotopic JM1 Liver Tumors
(A) Schematic depiction of the treatment schedule in a syngeneic tumor model in immunocompetent Fisher 344 rats inoculated intrahepatically with 1 105 JM1 hepatoma
cells. Intrahepatic JM1 tumors were injected intratumorally with (B) either sterile 0.9% NaCl (control) or 1.5 mg LTX-401 on two occasions (days 6 and 8) after tumor cell
inoculation. (C) Survival cures of animals treated with LTX-401. (D) Animals cured by LTX-401 treatment were 4 weeks later rechallenged subcutaneously with 1 105 viable
JM1 cells and monitored for tumor growth, whereas (E) indicates survival outcome after rechallenge. (F) A total of 1.0  106 splenocytes harvested from long-term survivors
(LTX-401) and naive control animals were co-cultured with 2.5 105 irradiated JM1 cells and incubated for 40 h at 37C. The number of IFN-g-producing cells in response to
tumor cell stimulation was evaluated using an ELISpot assay. The number of spots was counted in triplicate and counted automatically on an ELISpot counter. Top images
depict representative wells. (G) Ultrasound images depicting tumor and liver pre-treatment, 4 weeks post-treatment showing necrosis and fibrotic tissue, and 3months post-
treatment. Data depict the mean ± SEM and Student’s t test. The percentages of surviving animals were analyzed using a log rank Mantel-Cox test. ***p < 0.001. n, necrosis;
s.c., subcutaneous; T, tumor.
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Syngeneic JM1 HCC cells were harvested, washed in serum-free
RPMI 1640, and inoculated s.c. into the right side of the abdomen
in Fisher 344 rats (1  105 JM1 cells per rat/50 mL RPMI 1640).
Palpable tumors (60–90 mm3) were injected with single doses with
LTX-401 (0.4 mg/50 mL saline) for 3 consecutive days. Control ani-
mals received saline only (0.9% NaCl in sterile H2O). Subcutaneous
tumors were measured using an electronic caliper every 3 or 4 days.
Animals were euthanized with pentobarbital (0.1 mL/100 g intraper-
itoneally) if weight loss exceeded 15% of total body weight or if tumor
size exceeded 5,000 mm3. In addition, the following were imple-
mented as humane endpoints: signs of unacceptable pain, infection,
severe ulceration, or surgical complications.146 Molecular Therapy: Oncolytics Vol. 14 September 2019Secondary Tumor Challenge and Abdominal Surgery
Animals displaying complete regression of s.c. JM1 tumors were given
a second tumor challenge (s.c.) with JM1 cells (1  105 JM1 cells per
rat/50 mL RPMI 1640) into the left flank of the abdomen 4 weeks after
curative LTX-401 treatment. Animals surviving the s.c. tumor rechal-
lenge were additionally given an intrahepatic rechallenge by opening
the abdominal cavity through standard midline incision, while
releasing the liver from its ligamentous attachments. Next, an intra-
hepatic HCC tumor was established by the direct implantation of
JM1 cells into the inferior right lobe of the liver remnant using a
27G needle. In another set of experiments, LTX-401 (1.5 mg/50 mL
saline) was injected directly into orthotopic HCC tumors 6 and
8 days after tumor cell inoculation, following the exact procedures
Figure 8. Histopathological Examinations of JM1
Tumors
Representative images of tumor area from subcutaneous
and intrahepatic localized tumors, taken from both con-
trol animals (Ctrl) and animals treated with LTX-401
(7 days post-treatment). (A–D) Sections stained with
hematoxylin, eosin, and saffron (HES). (B and D) LTX-
401-treated tumors displayed large areas of necrotic
tumor tissue with small remaining nodules of vital tumor
tissue. (Q and R) Masson-trichrome staining (M-T) of the
liver tumors showed no fibrosis in control tumors and
only low levels of collagen at the border of the necrotic
tissue in LTX-401-treated animals. (E–H) Sections
immunostained for CD3+ T cells, (I–L) CD8+ T cells, and
(M–P) natural killer cells. Arrow points at border of tumor.
(A–D, Q, and R) Original magnification 20; scale bars,
500 mm. Insets in upper right corner show higher original
magnification of the tumors: 400. (E–P) Original
magnification 200; scale bars, 50 mm. gt, granulation
tissue; n, necrosis; T, tumor.
www.moleculartherapy.orgas previously described. In experiments examining the abscopal
effects of LTX-401 treatment, a s.c. tumor was established at day 0.
Next, an intrahepatic HCC tumor was established on day 6. The
s.c. tumor was injected in single doses with LTX-401 (0.4 mg/50 mL
saline) on days 7, 8, and 9. Care was taken to avoid post-surgical
pain and discomfort by the administration of 0.03–0.05 mg/kg bupre-
norphine s.c. (Temgesic; Reckitt), one dose before surgery and the
second dose 6 h later. Intrahepatic tumor was monitored and
measured in vivo by ultrasound imaging (Vevo 3100 system;
FUJIFILM VisualSonics). Tumor volumes were calculated using the
following formula: a  b2 (a being the width at the widest point of
the tumor, and b the width perpendicular to a).
ELISpot Assay
In brief, harvested splenocytes were plated at a density of 1.0 106 cells
and co-cultured with 2.5  105 irradiated JM1 cells and incubated for
40 h at 37C. Spots were developed according to the manufacturer’s
instructions (R&D Systems) and counted automatically on a
Immunospot analyzer (Cellular Technology) as a means of IFN-g
production.
Immunohistochemistry
Tumor samples were harvested and prepared for histological exami-
nation as previously described.38 Slides were incubated overnight atMolecular Th4C with primary antibody, rabbit polyclonal
anti-CD3 (clone A0452; Dako), mouse mono-
clonal anti-CD8 (clone OX-8; Abcam), or mouse
monoclonal anti-NK (clone ANK61; Santa
Cruz). As a secondary antibody, the anti-rabbit
horseradish peroxidase SignalStain Boost IHC
(immunohistochemistry) Detection Reagent
(Cell Signaling Technology) or anti-mouse-
HRP Envision+ System from Dako was used.A matched isotype control was used as a control for non-specific
background staining.Statistical Analysis
Results are presented as a mean ± SEM or SD of at least two indepen-
dent experiments. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) assays were conducted twice with three
parallels, and cytochrome c assays were conducted twice with two
parallels, whereas ATP assays were conducted three times with two
parallels. ELISpot IFN-g assay was conducted with splenocytes plated
in triplicates. Multiple comparisons (ATP and cytochrome c release
assays) were analyzed using Kruskal-Wallis test, whereas unpaired
events (abscopal tumor model experiments) were analyzed using
Mann-Whitney test. Two sets of data (ROS and ELISpot IFN-g
assays) were analyzed using Student’s t test. Survival curves were
generated with the Kaplan-Meier method and compared using the
Mantel-Cox test. All graphs and statistical analyses were performed
using Prism 6 software (GraphPad). p values% 0.05 were considered
to be statistically significant.SUPPLEMENTAL INFORMATION
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